Azoulay Daniel, Del Gaudio Massimo, Andreani Paola, Ichai Philippe, Sebag Mylène, Adam René, Scatton Olivier, Min Bao Yan, Delvard Valérie, Lemoine Antoinette, Bismuth Henri, Castaing Denis
Centre Hépato-Biliaire, Département de Chirurgie Hépato-Biliaire, Hôpital Paul Brousse, Villejuif, France.
Ann Surg. 2005 Jul;242(1):133-9. doi: 10.1097/01.sla.0000167848.96692.ad.
Although extensively studied in animal models, ischemic preconditioning has not yet been studied in clinical transplantation.
To compare the results of cadaveric liver transplantation with and without ischemic liver preconditioning in the donor.
Alternate patients were transplanted with liver grafts that had (n = 46, GroupPrecond) or had not (n = 45, GroupControl) been subjected to ischemic preconditioning. Liver ischemia-reperfusion injury, liver and kidney function, morbidity, and in-hospital mortality rates were compared in the 2 groups. Initial poor function was defined as a minimal prothrombin time within 10 days of transplantation <30% of normal and/or bilirubin >200 micromol/L.
The postoperative peaks of ASAT (IU/L) and ALAT (IU/L) were significantly lower in GroupPrecond (556 +/- 968 and 461+/-495, respectively) than in the GroupControl (1073 +/- 1112 and 997+/-1071, respectively). The rate of technical morbidity and the incidence of acute rejection were similar in both groups. Initial poor function was significantly more frequent in the GroupPrecond (10 of 46 cases) than in the GroupControl (3 of 45 cases). Hospital mortality rates were similar in the 2 groups. In multivariate analysis, body mass index of the donor, graft steatosis, and ischemic preconditioning were significantly predictive of the posttransplant peak of ASAT. In univariate analysis, only preconditioning was significantly associated with initial poor function.
Compared with standard orthotopic liver transplant, ischemic preconditioning of the liver graft in the donor is associated with better tolerance to ischemia. However, this is at the price of decreased early function. Until further studies are available, the clinical value of preconditioning liver grafts remains uncertain.
尽管在动物模型中已对缺血预处理进行了广泛研究,但尚未在临床移植中进行研究。
比较供体肝脏进行或未进行缺血预处理的尸体肝移植结果。
交替为患者移植经过(n = 46,预处理组)或未经过(n = 45,对照组)缺血预处理的肝脏移植物。比较两组的肝缺血再灌注损伤、肝肾功能、发病率和住院死亡率。初始肝功能不良定义为移植后10天内凝血酶原时间最低值<正常的30%和/或胆红素>200微摩尔/升。
预处理组术后谷草转氨酶(IU/L)和谷丙转氨酶(IU/L)的峰值(分别为556±968和461±495)显著低于对照组(分别为1073±1112和997±1071)。两组的技术并发症发生率和急性排斥反应发生率相似。预处理组初始肝功能不良的发生率(46例中有10例)显著高于对照组(45例中有3例)。两组的住院死亡率相似。多因素分析显示,供体的体重指数、移植物脂肪变性和缺血预处理是移植后谷草转氨酶峰值的显著预测因素。单因素分析显示,只有预处理与初始肝功能不良显著相关。
与标准原位肝移植相比,供体肝脏移植物的缺血预处理与更好的缺血耐受性相关。然而,这是以早期功能下降为代价的。在有进一步研究之前,肝脏移植物预处理的临床价值仍不确定。